Regenstrief names new CEO
Dr. Bill Tierney will replace Dr. Tom Inui on Oct. 1 at helm of Indianapolis-based medical research organization.
Dr. Bill Tierney will replace Dr. Tom Inui on Oct. 1 at helm of Indianapolis-based medical research organization.
Greatbatch Medical wants to expand its facility on the east side of Indianapolis to accommodate its entrance into the orthopedics
market. The
New York-based company specializes in cardiovascular products.
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
WellPoint Inc. has about $800 million riding on one arcane rule: how to calculate a medical loss ratio. The ratio quantifies
the percentage of customers’ premiums were spent on medical care, rather than overhead or profits.
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
More than 100 staff members of Indiana Medical Associates LLC likely will land at one of two area hospital systems. The move
mirrors national and local consolidation of practices with hospitals.
Attorney general seeks more details on the breach, which may have compromised financial and health information on almost 500,000
people. He also calls on the Indianapolis-based insurer to provide affected customers with credit monitoring and theft protection
services.
Burd, who is president of Burd Ford, a mother of four, and a fixture on television commercials for the dealership, has become
an advocate for mental health following her husband’s suicide.
About $72 million in bids have been awarded so far for the $754 million Wishard Hospital project—ahead of schedule
and under budget, for the time being—including demolition and foundation work.
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
The program currently includes 1,200 physicians—about 10 percent of all doctors in Indiana.
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
Indianapolis-based WellPoint Inc. said Wednesday that its California subsidiary will dial down rate hikes that drew national outrage earlier this year and helped spark a final push for health care reform.
Caregivers anticipates coping with declining Medicare reimbursements while having to offer insurance to its employees.
CNO Financial Group Inc. has finalized plans to set up a $10 million fund to settle a multistate investigation into increases
in policy costs.
As doctors threaten to drop Medicare patients, Congress delays cuts for another six months.
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
Indianapolis-based WellPoint Inc. says it notified 470,000 individual insurance customers about an online security breach
that may have exposed medical records, credit card numbers and other sensitive information.
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
U.S. health insurers are “moving towards an oligopoly,” a process that this year’s health-care overhaul
will accelerate, the investor-relations chief at WellPoint Inc. said Thursday.